Global Retinal Gene Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Indication;

Leber Congenital Amaurosis (LCA), Stargardt Disease, Choroideremia, X-linked Retinitis Pigmentosa (RP) and Others.

By End User;

Hospitals, Specialty Clinics and Academic Research Institutes.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn222031891 Published Date: March, 2025 Updated Date: May, 2025

Introduction

Global Retinal Gene Therapy Market (USD Million), 2021 - 2031

In the year 2024, the Global Retinal Gene Therapy Market was valued at USD 111.35 million. The size of this market is expected to increase to USD 198.51 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.6%.

The global retinal gene therapy market represents a rapidly evolving segment of the biotechnology industry, focused on developing and delivering innovative treatments for various retinal diseases. Retinal gene therapy involves the introduction of genetic material into a patient's cells to treat or prevent retinal disorders, which can lead to vision loss and blindness. These therapies target specific genetic mutations responsible for conditions such as Leber's congenital amaurosis, retinitis pigmentosa, and age-related macular degeneration.

Over the past decade, advancements in genetic research and technology have significantly accelerated the development of retinal gene therapies. The increasing understanding of the genetic underpinnings of retinal diseases has enabled researchers to design targeted treatments that can potentially restore vision or halt the progression of these debilitating conditions. Clinical trials are showing promising results, further fueling the optimism surrounding this field.

The aging global population is a major driver for the market, as age-related retinal diseases become more prevalent. Additionally, increased healthcare funding and strong industry partnerships are facilitating the research and development of novel gene therapies. Regulatory agencies are also showing supportive attitudes, streamlining approval processes to bring effective treatments to market faster.

Despite the positive outlook, the market faces several challenges. High treatment costs, complex regulatory requirements, and limited awareness among patients and healthcare providers can hinder market growth. Moreover, the ethical implications and potential side effects of gene therapy require careful consideration.

Nevertheless, the opportunities in the global retinal gene therapy market are substantial. Emerging markets present new growth avenues, and advancements in diagnostic techniques and personalized medicine are poised to enhance treatment efficacy. Strategic collaborations and government initiatives are further propelling the market forward, promising a future where retinal gene therapies could transform the lives of millions affected by vision impairments.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By End User
    3. Market Snapshot, By Region
  4. Global Retinal Gene Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advanced genetic research
        2. Increasing clinical trials
        3. Rising retinal diseases
        4. Technological advancements rapidly
        5. Growing aging population
      2. Restraints
        1. High treatment costs
        2. Regulatory approval complexities
        3. Limited market awareness
        4. Shortage of specialists
        5. Insufficient Insurance Coverage
      3. Opportunities
        1. Emerging market expansion
        2. Enhanced diagnostic techniques
        3. Strategic industry collaborations
        4. Personalized medicine growth
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Retinal Gene Therapy Market, By Indication, 2021 - 2031 (USD Million)
      1. Leber Congenital Amaurosis (LCA)
      2. Stargardt Disease
      3. Choroideremia
      4. X-linked Retinitis Pigmentosa (RP)
      5. Others
    2. Global Retinal Gene Therapy Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Academic Research Institutes
    3. Global Retinal Gene Therapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa

        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Gyroscope Therapeutics (Novartis)
      2. Applied Genetic Technologies Corporation (AGTC)
      3. Spark Therapeutics
      4. Adverum Biotechnologies
      5. REGENXBIO Inc.
      6. Biogen Inc.
      7. Nightstar Therapeutics
  7. Analyst Views
  8. Future Outlook of the Market